Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	1.06B
Revenue (ttm)	4.65M
Net Income (ttm)	-135.65M
Shares Out	55.89M
EPS (ttm)	-2.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,558
Open	18.99
Previous Close	18.89
Day's Range	18.78 - 19.65
52-Week Range	15.91 - 28.95
Beta	1.20
Analysts	Buy
Price Target	43.86 (+132.1%)
Earnings Date	Nov 3, 2022

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN...

• Industry: Biotechnology
• IPO Date: Jul 18, 2018
• CEO: R. Scott Struthers
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX

Full Company Profile

Financial Performance

In 2021, CRNX's revenue was $1.08 million, an increase of 1,418.31% compared to the previous year's $71,000. Losses were -$107.64 million, 45.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 43.86, which is an increase of 132.06% from the latest price.

Price Target

$43.86

(132.06% upside)

Analyst Consensus: Buy

Stock Forecasts